Abstract
Carbohydrate metabolism was evaluated by fasting and postprandial glucose, insulin, and hemoglobin (Hb)A1c levels in children with chronic renal insufficiency and various other growth disorders treated with growth hormone. Mean fasting and postprandial glucose remained unchanged throughout the 5-year study period in all four study groups. Median fasting insulin levels rose from lownormal levels into the normal range after 5 years of growth hormone. Average fasting insulin level after 5 years was 10 mU/l. Median postprandial insulin values also rose, yet remained within the normal range at the 5-year mark. Mean Hb A1c levels remained within low to middle end of the normal range in the patients with growth hormone deficiency, Turner syndrome, and idiopathic short stature. Mean Hb A1c levels at the 5 years were slightly elevated to 6.3% for the patients with chronic renal insufficiency.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fine RN, Kohaut EC, Brown D, Perlman AJ for the Genentech Collaborative Study Group (1994) Growth after recombinant human grwoth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind plaebocontrolled study. J Pediatr 124: 374–382
Fine RN, Attie KM, Kuntze J, Brown DF, Kohaut EC for the Genentech Collaborative Study Group (1995) Recombinant human growth hormone in infants and young children with chronic renal insufficiency. Pediatr Nephrol 9: 451–457
Rosenfeld RG, Frane J, Attie KM, Brasel JA, Attie KM, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J, Lippe BM, Mahoney PC, Moore WV, Saenger P, Johanson AJ (1992) Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. J Pediatr 121: 49–55
Attie KM, Chernausek S, Frane J, Rosenfeld RG for Genentech Study Group (1995) Growth hormone use in Turner syndrome: a preliminary report on the effect of early vs delayed estrogen. In: Albertsson-Wikland K, Ranke MB (eds) Turner syndrome in a life span perspective: research and clinical aspects. Elsevier Amsterdam, pp 175–181
Hintz RL, Attie KM, Johanson AJ, Baptista J, Roche AF and the Genentech Study Group (1995) Near final height in GH-treated short children without classical GH deficiency. Pediatr Res 37: 91A
Hopwood NJ, Hintz RL, Gertner JM, Attie KM, Johanson AJ, Baptista J, Kuntze J, Blizzard RM, Cara JF, Chernausek SD, Kaplan SL, Lippe BM, Plotnick LP, Saenger P (1993) Growth acceleration of non-growth hormone deficient children with marked short stature during three years of growth hormone therapy. J Pediatr 123: 215–222
Kaplan S, Underwood LE, August GP, Bell JJ, Blethen SL, Blizzard RM, Brown DR, Foley TP, Hintz RL, Hopwood NJ, Johansen A, Kirkland RT, Plotnick LP, Rosenfeld RG, Van Wyk JJ (1986) Clinical studies with recombinant-DNA-derived methionyl human growth hormone in growth hormone deficient children. Lancet I: 697–700
Tönshoff B, Haffner D, Mehls O, Dietz M, Ruder H, Blum WF, Heinrich U, Stoever B (1993) Efficacy and safety of grwoth hormone treatment in short children with renal allografts: three year experience. Kidney Int 44: 199–207
Saenger P, DiMartino-Nardi J (1992) Endocrine system in uremia. In: Edelmann CE (ed) Pediatric kidney disease, 2nd edn. Little Brown, Boston, pp 765–782
Tönshoff B, Tönshoff C, Mehls O, Pinkowski J, Blum WF, Heinrich U, Stoever B, Gretz N (1992) Growth hormone treatment in children with preterminal chronic renal failure: no adverse effect on glomerular filtration rate. Eur J Pediatr 151: 601–607
Walker J, Chaussain JL, Bougneres PF (1989) Growth hormone treatment of children with short stature increases insulin secretion but does not impair glucose disposal. J Clin Endocrinol Metab 69: 253–258
Saenger P, Attie K, Fine R, Hintz R, DiMartino-Nardi J and the Genentech Collaborative Group (1995) Metabolic consequences of 5 year growth hormone deficiency and other forms of short stature. Pediatr Res 37: 98A
Lesage C, Walker J, Landier F, Chatelain P, Chaussain JL, Bougneres PF (1991) Near normalization of adolescent height with growth hormone therapy in very short children without growth hormone deficiency. J Pediatr 119: 29
Saenger P, Wesoly S, Wasserman EJ, Glickstein J, Issenberg H (1996) Safety aspects of GH therapy in Turner syndrome (TS): no evidence for ventricular hypertrophy (VH) and normalization of insulin levels after discontinuation of GH. Pediatr Res 39: 98A
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Saenger, P., Attie, K.M., DiMartino-Nardi, J. et al. Carbohydrate metabolism in children receiving growth hormone for 5 years. Pediatr Nephrol 10, 261–263 (1996). https://doi.org/10.1007/BF00866753
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00866753